Utah Medical Products, Inc.

NASDAQ:UTMD

Medical - Instruments & Supplies

Healthcare
$72.24 +1.67%

+$1.10 today

Market cap
$205.81M
Beta
0.37
P/E (TTM)
19.6
EPS (TTM)
$3.41
Dividend yield
1.85%
52W Low $52.00High $71.81

Volume 0.02M

Average 0.01M

UTMD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Utah Medical Products, Inc.NASDAQ: UTMD

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $154K fell 0.6% year over year, ahead of the -5.0% change in trailing-twelve-month research & development. Sequentially, it fell 27.4% from the prior quarter. Over 3 fiscal years it compounded at +10.7% a year.

Context

  • Research & development amounted to 1.7% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -0.6% holds above the trailing-twelve-month pace of -5.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$154K-27.4% QoQ
Last fiscal yearDec 2025
$668K-17.8% YoY
LTMMar 2026
$668K-5.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.6%——
1 year-17.8%——
3-year CAGR+10.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
668K USD
Year-over-year change
-17.8%
4-year CAGR
+6.2%

Research & Development vs competitors

How UTMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.0% is the 7th highest of 10, against a peer median of +17.3%.
  • Research & development amounts to 1.8% of revenue for UTMD, versus a peer median of 34.5%.
UTMD Competitors
Research & Development for UTMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$102.32M USD+17.6%-19.3%218.2%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$85.68M USD+76.6%+218.7%13864.6%
OSUROraSure Technologies, Inc.LTM Mar 2026$46.23M USD+68.7%+5.5%40.9%
NYXHNyxoah S.A.LTM Mar 2026€42.56M EUR+17.3%+39.2%260.8%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$21.52M USD+58.7%-13.4%28.2%
PROFProfound Medical Corp.LTM Mar 2026$21.15M USD-1.0%+12.6%112.1%
STIMNeuronetics, Inc.LTM Mar 2026$6.33M USD-47.4%-11.0%4.2%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$4.59M USD-6.3%-4.0%10.6%
PREPrenetics Global LimitedLTM Mar 2026$4.57M USD-56.9%-5.0%4.0%
UTMDUtah Medical Products, Inc.LTM Mar 2026$668K USD-5.0%+10.7%1.8%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding UTMD) —+17.3%-4.0%34.5%

Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.05M52.28M50.22M40.9M38.52M
Cost of Revenue18.14M20.09M20.19M16.76M18.65M
Gross Profit30.92M32.2M30.04M24.14M19.88M
Gross Margin63.0%61.6%59.8%59.0%51.6%
Research & Development526K493K560K813K668K
Selling, General & Admin11.51M11.91M12.7M5.57M7.81M
Operating Expenses12.04M12.41M13.26M10.55M8.47M
Depreciation & Amortization7.28M7.08M6.37M2.77M2.95M
EBITDA26.35M27.74M24.75M19.57M17.06M
EBITDA Margin53.7%53.1%49.3%47.9%44.3%
Operating Income18.88M19.79M16.78M13.59M11.4M
Operating Margin38.5%37.9%33.4%33.2%29.6%
Interest Income166K661K03.37M0
Interest Expense00000
Other Income / Expenses181K869K3.31M3.21M2.71M
Income Before Tax19.06M20.66M20.09M16.8M14.11M
Pre-Tax Margin38.9%39.5%40.0%41.1%36.6%
Income Tax Expense4.27M4.19M3.45M2.93M2.82M
Net Income14.79M16.47M16.64M13.87M11.29M
Net Margin30.1%31.5%33.1%33.9%29.3%
EPS (Basic)4.054.534.573.963.41
EPS (Diluted)4.044.524.573.963.48
Weighted Avg Shares3.65M3.64M3.64M3.5M3.31M
Weighted Avg Shares (Diluted)3.66M3.64M3.64M3.5M3.24M

Utah Medical Products, Inc.

NASDAQ:UTMD

Intrinsic Alpha fair value

Locked

Current Price

$72.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.